NYSE · WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES · LARGE CAP
Accendra Health Inc/va/ ACH
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.8B
▲ 3.1% vs FY2024
EPS · FY25
$-14.31
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-1755.6%
Net margin · FY25
-39.8%
Dividend coverage
294.0×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.8B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
USD -14.31
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 294.0 times — the rest stayed in the company.
Profitability
-1755.6%
Return on equity, FY2025
ROE
Operating margin1.0%
Net margin-39.8%
Return on assets-31.0%
Each USD of equity lost 1756 cents this year.
Returned to shareholders
USD 10.2M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 10.2M
Share of profit-0.9%
Consecutive raises—
USD 10.2M in buybacks went back to shareholders in a year without profit.
Growth
−20.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−34.8%
−20.1%
−11.9%
−6.9%
Dividend / share
−77.3%
−60.3%
−35.5%
Returned to shareholders
+73.5%
−19.0%
−9.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years+4.0%
Change, 10 years+21.6%
The share count grew 4% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.5B
total assets, end of FY2025
Total assetsUSD 2.5B
EquityUSD -461.0M
CashUSD 282.0M
Gross debtUSD 2.0B
Net debtUSD 1.8B
Current ratio0.58×
Net debt stands at -384% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
2.8
2.7
2.6
10.0
9.8
8.5
9.2
9.4
9.3
9.7
9.8
9.4
9.1
8.9
8.6
8.1
8.0
7.2
Operating income $B
0.0
−0.2
0.1
0.1
0.4
0.2
0.1
−0.4
0.1
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
EBITDA $B
0.2
−0.0
0.3
0.4
0.5
0.3
0.2
−0.3
0.1
0.3
0.3
0.2
0.2
0.2
·
·
·
·
Income tax $B
0.0
0.0
0.0
−0.0
0.1
0.0
−0.0
−0.0
−0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Net income $B
−1.1
−0.4
−0.0
0.0
0.2
0.0
−0.1
−0.4
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
EPS, diluted $
−14.31
−4.73
−0.53
0.29
2.94
0.47
−1.03
−7.28
1.20
1.76
1.65
1.06
1.76
1.72
1.81
1.75
1.67
1.50
Dividend / sh $
·
·
·
·
0.01
0.01
0.01
0.86
1.03
1.02
1.01
1.00
0.96
0.88
0.80
0.71
0.61
0.53
Payout %
·
·
−0
0
0
2
−8
−11
87
58
62
95
55
51
44
40
37
35
ROE %
−1755.6
−47.4
−4.3
2.4
26.9
5.1
−12.7
−57.0
7.2
·
10.4
6.6
11.1
11.5
13.0
13.6
14.4
13.5
Shares out B
0.08
0.08
0.08
0.08
0.08
0.07
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
68 of 68
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed